Interactions between the cytochrome P450 system and the second-generation antipsychotics

Trevor I. Prior, MD, PhD; Glen B. Baker, PhD, DSc

Prior — Bebensee Schizophrenia Research Unit and Neurochemical Research Unit, Department of Psychiatry, University of Alberta and Alberta Hospital Edmonton; Baker — Department of Psychiatry, University of Alberta, Edmonton, Alta.

Awareness of the metabolism of second-generation antipsychotics by the cytochrome P450 (CYP) system can inform the clinician about how to avoid and manage drug–drug interactions involving these enzymes. Clozapine is metabolized primarily by CYP1A2, with additional contributions by CYP2C19, CYP2D6 and CYP3A4. Risperidone is metabolized primarily by CYP2D6 and to a lesser extent by CYP3A4. Olanzapine is metabolized primarily by CYP1A2 and to a lesser extent by CYP2D6. Quetiapine and ziprasidone are metabolized by CYP3A4. At the usual clinical doses, these drugs appear not to significantly affect the metabolism of other medications. There is, however, a lack of in vivo metabolic data, especially for the 3 newest second-generation antipsychotics: olanzapine, quetiapine and ziprasidone.

La connaissance du métabolisme des neuroleptiques de deuxième génération par le système cytochrome P450 (CYP) peut informer le clinicien sur la façon d’éviter et de prendre en charge les interactions entre médicaments qui mettent en cause ces enzymes. La clozapine est métabolisée principalement par l’enzyme CYP1A2 et les enzymes CYP2C19, CYP2D6 et CYP3A4 contribuent aussi au métabolisme. La rispéridone est métabolisée principalement par la CYP2D6 et, à un degré moindre, par la CYP3A4. L’olanzapine est métabolisée principalement par la CYP1A2 et, à un degré moindre, par la CYP2D6. La quetiapine et la ziprasidone sont métabolisées par la CYP3A4. Aux doses cliniques habituelles, ces médicaments ne semblent pas avoir d’effet significatif sur le métabolisme d’autres médicaments. On manque toutefois de données métaboliques in vivo, particulièrement dans le cas des trois neuroleptiques de deuxième génération les plus récents, soit l’olanzapine, la quetiapine et la ziprasidone.

Introduction

Schizophrenia is a chronic illness affecting approximately 1% of the population.1 Its pharmacologic management has changed over the past decade, in part owing to the acceptance of a new class of medications, generally termed atypical, novel or second-generation antipsychotics. These medications are reported to have a lower incidence of side effects than the older antipsychotics, and their use has arguably become first-
In this review, we will use the term second-generation antipsychotics to describe these medications. Coincidentally, there has been increased awareness among clinicians of the potential for pharmacokinetic drug–drug interactions and a greater understanding of the role that cytochrome P450 (CYP) enzymes may play in these interactions. Most individuals with schizophrenia take medications indefinitely and at some point take additional medications. Therefore, the risk of polypharmacy-related complications is very real in this population.

This article reviews the available data on the CYP-mediated metabolism of the commercially released second-generation antipsychotics clozapine, risperidone, olanzapine, quetiapine and ziprasidone. Non-CYP-mediated pathways, such as the phase II reaction glucuronidation, are involved in the metabolism of some second-generation antipsychotics but are not a focus of this review. We emphasize the potential for metabolic drug–drug interactions and, as much as possible, rely on data from in vivo studies of humans. Drug metabolism is summarized; comprehensive reviews are available elsewhere. We discuss the difficulties of interpreting the in vivo data, especially resolving conflicting data and generalizing the findings from controlled in vivo studies and case reports to clinical practice.

**Drug metabolism**

Pharmacologically active agents can interact at several levels, including drug metabolism. Drug metabolism can be defined as the chemical modification of the drug that occurs in a biologic environment. The primary role of drug metabolism is to facilitate the deactivation and excretion of the xenobiotic from the body. In addition, metabolism may result in the formation of active metabolites that have pharmacologic activities similar to those of the parent compound or altogether different biologic actions, including the ability to alter the metabolism of other chemical compounds.

The liver is the primary site of drug metabolism; other tissues, such as kidney, brain, skin, blood, lung and gastrointestinal mucosa, also contribute. Most medications are transformed in phase I or II reactions. Phase I reactions result in conversion of the parent drug, usually by oxidation, reduction or hydrolysis, to a more hydrophilic metabolite. Phase II reactions result in inactivation of the medication through chemically coupling to an endogenous substance, such as glucuronic acid, glycine, glutathione or glutamine, or conjugation with acetate, sulfate or methyl groups, thus facilitating renal excretion.

Oxidative reactions are among the most important of the phase I reactions. They are mediated by the family of enzymes that constitute the CYP system. At least 17 mammalian CYP gene families have been defined, and more than 30 human gene products have been identified. CYPs with 40% or greater DNA sequence homology are classified in the same family, and those with 55% or greater sequence homology are classified in the same subfamily. Thus, CYP3A4 is the designation of the CYP enzyme in family 3, subfamily A, gene product 4. Any drug may be a substrate for one or more CYPs.

Individual CYPs may be present in different forms or amounts in different people. Thus, people may be described as poor metabolizers (PMs) or extensive metabolizers (EMs) of certain drugs. It is generally well accepted that CYP2D6 and CYP2C19 exist as genetic polymorphisms. Ultrarapid metabolizers, with multiple copies of the CYP2D6 gene, have been identified. There is less support for polymorphisms for CYP1A2, CYP2A6 and CYP3A4.

Inhibition and induction of CYPs are among the most common causes of drug interactions. The role of polypharmacy in the development of medication-related side effects is not limited to simple competition for a specific CYP. A drug (or its metabolites) may be a substrate for, and an inhibitor or inducer of, the same CYP. Further, a drug (or its metabolites) may alter the activity of a specific CYP without being a substrate. Thus, concomitantly prescribed medications may affect the serum levels of substrates of those CYPs.

Drug interaction at the CYP level has been reviewed recently. Direct drug (or metabolite) interaction with CYPs may cause inhibition by 1 of 3 broad mechanisms: reversible inhibition, quasi-irreversible inhibition and irreversible inhibition. In vivo, the last 2 inhibition subtypes are, for practical purposes, equivalent, causing a loss of a CYP’s activity through formation of a covalently (irreversibly) modified enzyme–drug complex or a drug–enzyme complex that is bound so tightly that dissociation is unlikely ( quasi-reversible); in both cases, there is lowered Vmax and capacity. In either case, restoration of normal CYP activity requires synthesis of new enzyme. With reversible inhibition, normal function can be restored rapidly after the inhibiting agent is removed from the body; there is competition between the inhibitor and the second-
interaction antipsychotic for the CYP, with an increase in $K_m$ but an unaltered $V_{max}$. CYP activity also can be increased by medications, usually through increased production of the enzyme. Known to be inducible are CYP1A1, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2E1 and CYP3A4. In contrast to inhibition, induction via increased CYP levels is slow. Allosteric interaction, binding of a drug (or metabolite) to a site on the enzyme removed from the active site, may result in a more active CYP and would occur more quickly. It is not always possible to definitively identify whether a specific CYP is involved in the metabolism of a particular drug. A number of in vitro approaches have been used to investigate and predict drug–CYP interactions. Generally, the drug is incubated in the presence of human liver tissue (liver slices, microsomes, subcellular fractions of hepatic tissues or cultured hepatocytes) or microsomes prepared from various cell systems in which specific cDNAs for human CYPs are expressed, and the production of specific metabolites or a decrease in the amount of parent drug is measured. Refinements include the use of selective CYP inhibitors, probe substrates (drugs known to be metabolized by a specific CYP) or monoclonal antibodies to a particular CYP. Interpretation of the results, particularly as to their predictive clinical value, has been reviewed. Similarly, a number of approaches have been used in vitro to assess the ability of drugs to induce CYPs. However, although in vitro investigations can provide information on whether a drug (or metabolite) is a substrate, inhibitor or inducer of a particular CYP, the contribution of each CYP to the drug’s metabolism in vivo is speculative.

There have been few controlled in vivo studies of drug metabolism. In some, human volunteers have received a known inhibitor or inducer of a specific CYP along with the drug under investigation. The rates of clearance of the drug in the presence and absence of the inhibitor or inducer are compared to determine whether the CYP is involved in the drug’s metabolism. Another in vivo approach has been to exploit known genetic polymorphisms and their effects on drug metabolism, clearance, inhibition and induction. The subject is identified as being a PM or an EM, and the rate of metabolism of the specific drug is measured. This type of study is limited to the CYPs for which there are known polymorphisms that affect activity.

For the most part, data on the in vivo metabolism of a drug by a specific CYP have been derived from case reports on individuals who have received medications concurrently. The role of a particular CYP can only be inferred from these studies. It is possible, for example, that the observed clinical effects resulted from interactions other than CYP-mediated metabolism in the liver. Results in case reports should be taken as suggestive, not conclusive. Case reports are by definition noncontrolled. Factors such as diet, other illnesses and polymorphic status can profoundly affect a drug’s metabolism. Furthermore, results are often from a single or very few individuals, and blood samples may have been drawn without due consideration of the time since the last dose. Recently, a number of case series have been published in which individuals receiving a second-generation antipsychotic were treated with a second medication known to be metabolized by, or to inhibit or induce, a particular CYP. The effect on the serum level of the antipsychotic was measured. As discussed by Lin and Lu, results from these studies can be difficult to interpret and generalize from, given the interindividual variability of CYP activity in humans. This variability stems from a number of factors, including the distribution of CYPs in other tissues, the polymorphic status of the individual (with respect to absolute CYP amounts, CYP activity and sensitivity to inhibitors and inducers), age, health status and environmental factors such as diet and cigarette smoking. For example, EMs are more susceptible to enzyme inhibition than are PMs. Furthermore, a particular drug may be metabolized by more than one CYP; thus, inhibiting one CYP may not result in a significant change in serum levels.

### Clozapine (Table 1)

Clozapine was the first second-generation antipsychotic released for clinical use. Consequently, there are more data available on its metabolism than on other medications in this class. Byerly and DeVane, as well as Taylor, have reviewed the pharmacokinetics of clozapine.

#### CYP1A1

We did not identify any in vivo studies that implicated CYP1A1 in the metabolism of clozapine. However, Fang and colleagues, in an in vitro study, failed to find evidence supporting a role for this enzyme in the metabolism of clozapine.
CYP1A2

It seems well established that CYP1A2 is involved in the metabolism of clozapine. Pirmohamed and associates, using enzyme-selective inhibitors in vitro, showed that CYP1A2 catalyzes the demethylation of clozapine. Using a variety of in vitro techniques, including human liver microsomes, chemical inhibitors, CYP-specific antibodies and a yeast expression system to express CYP1A2, Eiermann and coworkers also were able to demonstrate involvement of this enzyme. Linnet and Olesen obtained similar results using commercial microsomes prepared by means of cDNA expression, although they suggested that CYP1A2 was likely to play only a minor role in the in vivo metabolism of clozapine at therapeutic concentrations. More recently, the same authors, using a lower, more therapeutic concentration of clozapine, found that CYP1A2 and CYP2C19 were most responsible for clozapine demethylation in vitro, CYP2C9 and CYP2D6 playing a more modest role. At higher concentrations of clozapine, CYP3A4 becomes more relevant. Fang and colleagues demonstrated that CYP1A2 could catalyze both demethylation of clozapine and the formation of clozapine-N-oxide, although its role in the formation of the latter is likely similar. Similarly, Tugnait et al reported that inhibition of CYP1A2 in vitro by antibodies or chemical inhibitors affected both demethylation and oxidation of clozapine significantly but that the effect on the former was greater in magnitude.

Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), inhibits both CYP1A2 and CYP2C19. Using human hepatocyte microsystem preparations, Chang and colleagues noted that fluvoxamine caused 48.5% inhibition of clozapine metabolism; 42.0% inhibition was observed with the chemical CYP1A2 furafylline. Similarly, Olesen and Linnet noted significant inhibition of clozapine demethylation in vitro after incubation with fluvoxamine, a reaction catalyzed in vitro by CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. However, since fluvoxamine has a lower, more therapeutically relevant concentration, the result is probably due primarily to inhibition of 1 of these 2 enzymes.

One method of determining CYP1A2 polymorphism is to measure the clearance rate of caffeine, a substrate of this enzyme. Bertilsson and associates observed that individuals who rapidly cleared caffeine had lower serum levels of clozapine after receiving a single dose of this medication. Bender and Eap observed that in 2 individuals who were not responding clinically to clozapine, there was a similar correlation between rapid clearance of caffeine and low serum levels of clozapine; a third individual who was not responding to clozapine did not have rapid caffeine clearance. After reviewing drug-monitoring data (dose and serum levels), Jerling and coworkers demonstrated, using nonparametric statistical methods, a similarity in the distribution of clozapine clearance rates and CYP1A2 phenotype in the population.

There is growing evidence that interactions between clozapine and caffeine may be clinically relevant. Vanier and Chouinard described an individual being treated with clozapine who showed signs of increased arousal and extrapyramidal symptoms after consuming caffeinated beverages; the signs and symptoms resolved when noncaffeinated drinks were substituted. Clozapine levels were not measured, but, because the reaction was acute, the authors concluded that it was due to potentiation of dopamine D2-receptor stimulation secondary to the dopamine D1-agonist and adenosine A2-antagonist activity of caffeine. Odom-White and de Leon observed an increase in serum levels of both clozapine and norclozapine in a patient who consumed an excessive daily amount of caffeine (more than 1200 mg). Carrillo et al reported a case series in which serum levels of clozapine, norclozapine and clozapine-N-oxide were measured in 7 patients initially, after 5 days without caffeine and 2 weeks after reintroduction of caffeine. They noted a statistically significant reduction in levels of clozapine (47%) and clozapine-N-oxide (31%) and a significant increase.

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Involved in metabolism of clozapine</th>
<th>In vitro</th>
<th>Case reports</th>
<th>Case series</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A1</td>
<td>−</td>
<td>−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP1A2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>CYP2C8</td>
<td>+ (NC)</td>
<td>+ (NC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2C9</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2C19</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2D6</td>
<td>+ (NC)</td>
<td>+ (NC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2E1</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP3A4</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: All studies were performed on humans or human tissue. + = data support role; − = data do not support role; +/− = data are contradictory; NC = likely not clinically relevant. Space left blank if no data available. The above footnotes apply to all tables in this article.
(185%) in the ratio of norclozapine to clozapine levels after caffeine was removed from the diet; the ratio correlated with CYP1A2 activity, as measured by the caffeine clearance rate. All serum levels returned to the original values after caffeine was reintroduced.

Cigarette smoking induces CYP1A2. Smokers have been observed to have lower serum levels of clozapine than nonsmokers, sometimes significantly lower and sometimes not. This interaction can have clinical significance. Two patients receiving clozapine had seizures after they stopped smoking. The seizures were attributed to elevated serum levels of clozapine, although the levels were not measured. After recovery, 1 of the patients required a 40% reduction in the dose of clozapine.

Increased serum levels of clozapine (and norclozapine) after the start of fluvoxamine treatment have been reported from several cases and some of the patients had side effects indicative of elevated clozapine levels. The clozapine levels returned to normal when fluvoxamine was discontinued. The effects of fluvoxamine on clozapine serum levels have also been studied prospectively. Wetzel and associates treated individuals who had stable serum clozapine levels with fluvoxamine and found significant increases in the serum levels of clozapine, N-desmethylclozapine and clozapine-N-oxide; they estimated that the elimination half-life of clozapine tripled. Chang and colleagues treated 9 men with schizophrenia with fluvoxamine for 2 weeks. Immediately before and on the last day of fluvoxamine treatment, they administered a single dose of clozapine and measured the serum levels of the antipsychotic and its metabolites over a 48-hour period. They observed a significant increase in clozapine level and patient sedation with the second dose. The serum levels of the metabolites decreased transiently after fluvoxamine treatment.

Although the interaction between clozapine and fluvoxamine has been viewed primarily in terms of negative outcomes resulting from excessive serum levels of clozapine, it could have a benefit. Lammers and coworkers treated patients concomitantly with fluvoxamine and a titrating dose of clozapine, obtaining therapeutic serum levels of clozapine with relatively low daily doses (i.e., 96.9 ± 37.2 mg); the patients had clinically significant reductions of symptoms while avoiding the sedation associated with the usual initial doses of clozapine. In a similar study, Lu et al treated patients with clozapine at a daily dose of 100 mg; after adding fluvoxamine to the regimen, they observed a significant increase in clozapine serum levels that coincided with clinical relief in two-thirds of the patients, without significant side effects.

Further data supporting a role for CYP1A2 in the metabolism of clozapine comes from publications on the effects of treatment with antibiotics. Joos, Frank and Kaschka described a patient in whom the serum clozapine level decreased and symptoms re-emerged upon treatment with rifampin (an inducer of both CYP1A2 and CYP3A), isoniazid (a general inducer of CYPs) and pyrazinamide. The symptoms resolved when the clozapine dose was increased. When the rifampin was replaced with ciprofloxacin (an inhibitor of CYP1A2), the serum clozapine level increased 60% despite lowering of the dose of clozapine. Similarly, Fuhr and colleagues noted an 80% increase in serum clozapine levels resulting from treatment with the CYP1A2 inhibitor fluoroquinolone. In a randomized double-blind crossover study, Raaska and Neuvonen found that individuals with schizophrenia who were clinically stable with clozapine treatment had a significant increase in plasma clozapine and N-desmethylclozapine levels when treated additionally with ciprofloxacin as compared with placebo; the increases correlated with the concentration of ciprofloxacin in the blood.

CYP2C subfamily

Compared with CYP1A2, relatively few data are available on the role of the CYP2C subfamily in the metabolism of clozapine. Eiermann and coworkers reported that CYP2C8 is not involved in the metabolism of clozapine in vitro. In contrast, the study of Fang and colleagues indicated that this enzyme could catalyze the N-demethylation of clozapine and the formation of clozapine-N-oxide in vitro, although to a lesser extent than CYP1A2 and CYP3A4. In vitro studies have shown that CYP2C9 can demethylate clozapine, although clinically, its role is likely minor. The same authors independently reported that CYP2C19 could metabolize clozapine in vitro, although they disagreed about this enzyme’s in vivo relevance; Linnet and Olsen concluded that it might account for up to 35% of in vivo metabolism. As discussed earlier, fluvoxamine can cause clinically relevant increases in serum clozapine levels, although it is a more potent inhibitor of CYP1A2 than of CYP2C19. The in vivo role of
CYP1A2 is supported by reports not involving fluvoxamine; confirmation of an in vivo role for CYP2C19 in the metabolism of clozapine requires additional study.

**CYP2D6**

The evidence concerning the role of CYP2D6 in the metabolism of clozapine is contradictory. In vitro studies using microsomal preparations of cDNA-expressed CYP2D6 have indicated that this enzyme can catalyze the metabolism of clozapine. However, there is some question about whether the degree of metabolism seen is clinically relevant. Eiermann and coworkers reported that this enzyme was not involved in the in vitro metabolism of clozapine. Using liver preparations from PMs and EMs, Pirmohamed and associates found no correlation between the CYP2D6 phenotype and the in vitro degradation of clozapine.

A number of SSRIs inhibit CYP2D6. Eggert, Crismon and Dovjon reported a case in which there was no change in serum levels of clozapine after the individual taking this medication was started on fluoxetine therapy. In contrast, Joos and associates observed a clinically significant increase in clozapine levels 19 days after the start of paroxetine treatment in a patient who was an EM. As Lin and Lu noted, such individuals are more susceptible to the effects of concomitantly prescribed inhibitors. In a larger, naturalistic study, Centorrino et al reported that individuals treated with clozapine alone had significantly lower serum levels than patients who were concomitantly treated with paroxetine, fluoxetine or sertraline. Previously, they had reported that only 4 of 8 patients had elevated levels of clozapine after being treated with fluoxetine. In a prospective study, Spina and coworkers described patients who experienced a 2-fold increase in serum clozapine level after taking the CYP2D6 substrate risperidone.

In all but 1 of the studies concerning CYP2D6, the patients were not characterized by polymorphic status, and it is possible that some of the discrepancies reflect this fact. Two studies attempted to correlate polymorphic status of CYP2D6 with clozapine levels; neither was able to do so. The in vivo metabolism of clozapine by CYP2D6 may not generally be clinically significant. However, individuals who are CYP2D6 EMs, and therefore more susceptible to inhibition of this enzyme, and have a PM phenotype for another CYP involved in clozapine metabolism (such as CYP1A2) may be more sensitive to drug–drug interactions related to CYP2D6.

**CYP2E1**

From in vitro studies, CYP2E1 does not appear to be involved in the metabolism of clozapine.

**CYP3A4**

Several in vitro studies have indicated that clozapine metabolism can be catalyzed by CYP3A4. From in vitro stimulation studies, Linnet and Olesen concluded that this enzyme may be responsible for up to 35% of clozapine metabolism in vivo. However, more recently, they reported that at therapeutic concentrations of clozapine the role of CYP3A4 may be minor. Tugnait et al reported that, whereas CYP1A2 was more important in N-demethylation of clozapine, CYP3A4 was more important in N-oxidation.

Few in vivo studies have investigated the role of CYP3A4 in the metabolism of clozapine. After taking erythromycin, an inhibitor of CYP3A4, 2 patients had side effects consistent with clozapine toxicity and elevated serum levels; after the antibiotic was discontinued, the side effects resolved and the serum levels of clozapine fell. However, human volunteers showed no significant changes in the serum concentration or rate of renal clearance of clozapine or its metabolites after a single dose when also treated with erythromycin. Concomitant administration of nefazodone, an inhibitor of CYP3A4, has been shown to result in a dose-dependent increase in the serum clozapine level. However, in 6 patients with schizophrenia, Taylor et al observed only minor increases in the serum levels of clozapine (4%) or norclozapine (16%) after nefazodone was introduced. They did not report the serum levels of clozapine-N-oxide but did note that some subjects had more significant increases in the levels of clozapine and norclozapine; perhaps these subjects were CYP1A2 PMs and therefore more dependent on alternative pathways of clozapine metabolism. Raaska and Neuvonen had similar
negative results using the CYP3A4 inhibitor itraconazole. They too did not report clozapine-N-oxide serum levels but noted that a patient who was also receiving fluoxetine experienced a moderate elevation in levels of both clozapine and desmethyl-N-clozapine. Thus, it seems likely that CYP3A4 is involved in the metabolism of clozapine, although clinically significant interactions may occur only in individuals with impaired alternative pathways of metabolism, such as via CYP1A2.

**Inhibition or induction of CYPs by clozapine**

Clozapine may affect the CYP-mediated metabolism of other medications. However, in vivo data are lacking. Ring and colleagues reported from in vitro studies that clozapine can inhibit CYP2C9, CYP2C19, CYP2D6, and CYP3A, the $K_i$ values being 31 $\mu$M, 69 $\mu$M, 19 $\mu$M and 99 $\mu$M, respectively. Shin, Soukhova and Flockhart reported $K_i$ values from studies with different metabolic substrates of CYP1A2 (> 300 $\mu$M), CYP2C9 (31 $\mu$M), CYP2C19 (> 300 $\mu$M), CYP2D6 (39 $\mu$M) and CYP3A (> 300 $\mu$M) and predicted from these results that there would be no inhibition by clozapine of these CYPs in vivo. However, Smith and Risken reported a doubling of the serum levels of nortriptyline (a CYP2D6 substrate) after a patient was started on clozapine therapy. Clozapine may accumulate in the liver and thus inhibit CYPs. Alternatively, perhaps clozapine’s metabolites are more potent inhibitors than the parent drug and are responsible for any observed clinical interactions; the in vitro studies were performed only with clozapine.

The only reported investigations into the potential of clozapine to induce CYPs have been in vitro studies using nonhuman tissues. Incubation of rat tissues with clozapine resulted in increased levels of CYP1A, CYP2B and CYP3A but not CYP2D. The clinical relevance of these findings is unclear. Nonetheless, the lack of reports indicating an effect on the metabolism of other prescribed drugs since clozapine was introduced for clinical use suggests that any inhibition or induction is insignificant.

**Risperidone (Table 2)**

Compared with clozapine, few publications have reported potential drug–drug interactions involving risperidone. The paucity of data may reflect a relative lack of clinical experience with this medication, although given the time the drug has been available, this seems unlikely. Rather, the lack of publications on adverse events likely reflects either greater safety or a lack of recognition that symptoms are due to interactions with CYPs. Caccia recently reviewed the metabolism of risperidone.

**CYP1A subfamily**

In vitro studies using human liver microsomes and recombinant human CYP1A1 and CYP1A2 failed to find evidence of the involvement of either enzyme in the metabolism of risperidone.

**CYP2C subfamily**

Risperidone is not metabolized by CYP2C9 or CYP2C19 in vitro.

**CYP2D6**

In vitro studies have shown that CYP2D6 catalyzes the metabolism of risperidone to its major metabolite, 9-hydroxyrisperidone. Several studies have attempted to correlate CYP2D6 polymorphic status with serum levels of risperidone and 9-hydroxyrisperidone. Using a single-dose model in human volunteers, Huang and associates observed a correlation between polymorphic phenotype and the formation of 9-hydroxyrisperidone. In a cross-sectional study, Olesen and coworkers noted that patients who were CYP2D6 PMs had an increased ratio of risperidone to 9-hydroxyrisperidone but no difference in total concentration of the active moiety (risperidone plus 9-hydroxyrisperidone). Further, they found no correlation between side effects and polymorphic status.

### Table 2: Interaction between CYPs and risperidone

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>In vitro</th>
<th>In vivo</th>
<th>Inhibited by risperidone: In vitro data only</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A1</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CYP1A2</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CYP2C9</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CYP2C19</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CYP2D6</td>
<td>+</td>
<td>+</td>
<td>+ (NC)</td>
</tr>
<tr>
<td>CYP3A4</td>
<td>+/-</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

**Table 2: Interaction between CYPs and risperidone**

In summary, the interactions of risperidone with CYPs appear to be minimal compared to clozapine. Further studies are needed to fully understand the potential interactions of risperidone with CYPs.
Similarly, Scordo et al.\textsuperscript{101} and Bork and colleagues\textsuperscript{102} reported a correlation between polymorphic status and serum risperidone but not 9-hydroxyrisperidone levels. Bork and colleagues observed that patients who were genotypically CYP2D6 PMs were more likely to stop treatment with risperidone, although they noted limitations to the study design. Spina and associates,\textsuperscript{103} in a prospective study of 10 patients stabilized on risperidone therapy who were concomitantly given the CYP2D6 inhibitor paroxetine, found a significant increase in the serum level of risperidone but not 9-hydroxyrisperidone; only 1 patient had side effects (parkinsonian symptoms) that might have been attributable to the increase.

Recently, there has been an increased interest and awareness of the potential differences in clinical efficacy of enantiomers (nonsuperimposable mirror images, akin to the right and left hand) of drugs.\textsuperscript{104,105} Risperidone does not have a chiral centre, but one is formed when it is metabolized to 9-hydroxyrisperidone, the result being stereoisomers. Yasui-Furukori and coworkers\textsuperscript{106} have demonstrated that CYP2D6 plays a predominant role in the formation of (+)-9-hydroxyrisperidone in vivo.

### CYP3A4

Initial in vitro investigations did not indicate a role for CYP3A4 in the metabolism of risperidone.\textsuperscript{96} However, Fang, Bourin and Baker\textsuperscript{97} noted that ketoconazole (an inhibitor of CYP3A4) could inhibit the formation of 9-hydroxyrisperidone in vitro. Bork and colleagues\textsuperscript{102} noted in their study a number of cases in which inhibitors and inducers of CYP3A4 affected the serum levels of risperidone and had potential clinical significance. One patient receiving the CYP3A4 inducer carbamazepine had a doubling in the serum level of 9-hydroxyrisperidone and severe akathisia after the anticonvulsant was discontinued. Another patient had akathisia, parkinsonian symptoms and a significant elevation in the serum level of 9-hydroxyrisperidone after the CYP3A4 inducer mesotidazine was discontinued. A patient receiving the CYP3A4 inhibitor nefazodone experienced similar symptoms, although the serum levels of risperidone and 9-hydroxyrisperidone in the absence of nefazodone treatment were not reported. De Leon and Bork\textsuperscript{107} reported a case in which the 9-hydroxyrisperidone level doubled after carbamazepine was discontinued.

Spina et al.\textsuperscript{108} observed that individuals receiving carbamazepine but not sodium valproate had lower serum levels of risperidone and 9-hydroxyrisperidone than controls, although only the difference in the levels of the metabolite was statistically significant. In all the reports involving CYP3A4, only the level of 9-hydroxyrisperidone seemed to be affected by alterations in CYP3A4 activity; this may indicate that CYP3A4 is involved predominantly in the metabolism of 9-hydroxyrisperidone. Interestingly, Spina and colleagues\textsuperscript{109} noted a decrease in the plasma levels of both risperidone and 9-hydroxyrisperidone and an exacerbation in psychotic symptoms after carbamazepine was taken by a patient who was a CYP2D6 PM.

Formation of 9-hydroxyrisperidone has the potential to result in the production of enantiomeric isomers. Ketoconazole inhibits the formation of (-)-9-hydroxyrisperidone,\textsuperscript{106} suggesting that the metabolism of risperidone by CYP3A4 results in the synthesis of this specific enantiomer. The clinical significance of this finding remains to be determined.

**Inhibition of CYPs by risperidone**

Risperidone apparently does not inhibit CYP1A2, CYP2C9, CYP2C19 or CYP3A. Its minor inhibition of CYP2D6 is likely not clinically relevant at therapeutic doses of the antipsychotic.\textsuperscript{92,110}

### Olanzapine (Table 3)

The role of CYPs in the metabolism of olanzapine has become clearer in recent years. Callaghan and associates\textsuperscript{111} reviewed the pharmacokinetics and pharmacodynamics of olanzapine. Markowitz and coworkers\textsuperscript{112} recently found that human volunteers treated with the glucuronidation inhibitor probenecid showed statistically significant changes in plasma pharmacokinetic

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Involved in metabolism of olanzapine</th>
<th>In vitro</th>
<th>In vivo</th>
<th>Case reports</th>
<th>Case series</th>
<th>Inhibited by olanzapine; in vitro data only</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>(NC)</td>
<td>–</td>
</tr>
<tr>
<td>CYP2C9</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2D6</td>
<td>+</td>
<td>+</td>
<td>(NC)</td>
<td></td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>CYP3A4</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
parameters that were not reflected in the serum clearance of olanzapine.

**CYP1A2**

From in vitro studies, Ring et al.\(^{113}\) suggested that CYP1A2 was responsible for the formation of N-desmethylolanzapine. Callaghan and associates\(^{111}\) noted that the formation of this metabolite correlated significantly with olanzapine clearance rates in vitro.

In a placebo-controlled study, Mäenpää and colleagues\(^{114}\) observed that concomitant treatment with the CYP1A2 inhibitor fluvoxamine resulted in increased serum levels and decreased rates of clearance of olanzapine, along with decreased serum levels of N-desmethylolanzapine.\(^{114}\) Similarly, in a single patient, Markowitz and DeVane\(^{115}\) noted that concomitant treatment with the CYP1A2 inhibitor ciprofloxacin resulted in a doubling of the serum olanzapine levels that reversed when the antibiotic was discontinued;\(^{115}\) the patient did not have side effects attributable to the increased levels of the antipsychotic. Further support for an in vivo role for CYP1A2 in the metabolism of olanzapine comes from the observation by Callaghan and associates\(^{111}\) that smokers had lower serum levels and higher clearance rates than nonsmokers.

Carbamazepine induces both CYP1A2 and CYP3A4.\(^{116}\) Two groups of investigators\(^{117,118}\) reported a decrease in serum olanzapine levels when patients were treated concomitantly with this anticonvulsant. Owing to a lack of evidence supporting a role for CYP3A4 in the metabolism of olanzapine, they concluded that the effects of carbamazepine on olanzapine metabolism were via induction of CYP1A2.

**CYP2D6**

CYP2D6 appears to be responsible for the formation of the metabolite 2-hydroxyolanzapine in vitro.\(^{113}\) Callaghan and associates\(^{111}\) found that concomitant treatment with the CYP2D6 inhibitor fluoxetine resulted in a doubling of the serum olanzapine levels that reversed when the antibiotic was discontinued;\(^{115}\) the patient did not have side effects attributable to the increased levels of the antipsychotic.

**CYP3A4**

There is no evidence, including in vitro data,\(^{115}\) supporting a role for CYP3A4 in the metabolism of olanzapine.

**Inhibition of CYPs by olanzapine**

Olanzapine does not inhibit CYP1A2, CYP2C9, CYP2D6 or CYP3A\(^{111,113}\) in vitro at \(K_i\) values that appear to be clinically relevant. Macias and associates\(^{119}\) reported that olanzapine did not affect the metabolism of the CYP1A2 substrate theophylline in vitro.

**Quetiapine (Table 4)**

Quetiapine has been available commercially for a relatively short time. Consequently, clinical data on potential drug–drug interactions are lacking. Dev and Raniwalla\(^{120}\) have reviewed quetiapine’s clinical safety.

**CYP1A2**

According to the manufacturer, quetiapine is not metabolized by CYP1A2.\(^{120}\) Goldstein\(^{121}\) reported that cigarette smoking does not affect the pharmacokinetics of this drug.

**CYP2C19**

According to the manufacturer, quetiapine is not metabolized by CYP2C19.\(^{122}\)

**CYP2D6**

According to the manufacturer, the metabolism of quetiapine is altered insignificantly by concomitant administration of imipramine or fluoxetine.\(^{120}\) Thus, it is unlikely that CYP2D6 is involved in the in vivo metabolism of quetiapine.

**CYP3A4**

According to the manufacturer, quetiapine is primarily

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Involved in metabolism of quetiapine</th>
<th>In vitro</th>
<th>Case reports</th>
<th>Case series</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CYP2C9</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CYP2C19</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CYP2D6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CYP3A4</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>
metabolized by CYP3A4. In a multiple-dose study, concomitant administration of the CYP3A4 inhibitor ketoconazole resulted in a significant increase in serum quetiapine levels and half-life. Concomitant administration of the CYP inducer phenytoin resulted in a significant decrease in serum quetiapine levels that corresponded with an increase in clearance rates; the investigators concluded that since quetiapine is primarily metabolized by CYP3A4, the observed pharmacokinetic changes were due to induction of CYP3A4. Savasi, Millson and Owen reported a case in which the serum levels of quetiapine increased 24-fold after concomitant phenytoin administration was stopped and another case in which the serum levels of quetiapine decreased with concomitant administration of the CYP3A4 inducer carbamazepine.

**Inhibition or induction of CYPs by quetiapine**

According to the manufacturer, quetiapine does not affect the metabolism of compounds known to be metabolized by CYP1A2, CYP2C9, CYP2D6 or CYP3A4. Ziprasidone (Table 5)

Ziprasidone has only recently been released to the market. Using human liver microsomes, CYP-specific inhibitors and recombinant enzymes, Prakash and coworkers found no evidence supporting a role for CYP1A2, CYP2C9, CYP2C19 or CYP2D6 in the metabolism of this drug in vitro.

**CYP3A4**

In vitro data indicate that CYP3A4 is the primary CYP involved in the metabolism of ziprasidone. As expected, Prakash and coworkers found that concomitant administration of CYP3A4 inhibitors altered the drug’s pharmacokinetics. In an open-label, randomized, crossover study, Micelli et al observed a statistically significant increase in serum levels of this antipsychotic when administered along with ketoconazole.

**Inhibition of CYPs by ziprasidone**

In vitro data indicate that, although ziprasidone can inhibit CYP2D6 and CYP3A4, the K values are such that in vivo inhibition is unlikely at clinical doses of the drug. This finding is supported by the observation that ziprasidone did not alter the metabolism of the CYP2D6 substrate dextromethorphan in vivo.

**Conclusions**

Clozapine is metabolized by both CYP1A2 and CYP3A4. Concomitant use of this medication and inhibitors of these enzymes should be carried out with caution and adequate supervision. In addition, individuals who are EMs because of multiple copies of the CYP2D6 gene may be susceptible to side effects when treated concomitantly with clozapine and CYP2D6 inhibitors.

Risperidone is metabolized primarily by CYP2D6 and to a lesser degree by CYP3A4. Although polypharmacy can result in elevated serum levels of the antipsychotic, the risks of inhibiting its metabolism appear to be minimal. Among the second-generation antipsychotics, risperidone seems to have the greatest ability to inhibit the metabolism of other medications, but the risk is low at the usual clinical doses.

The 3 newest antipsychotics were approved for commercial release in a regulatory environment in which data about the drug’s metabolism and the potential risks of polypharmacy, particularly in relation to the CYP enzymes, are required and reviewed before approval. This fact, combined with the relatively short period of availability, may account for the lack of data in the scientific literature on the metabolism of these medications. Olanzapine is metabolized primarily by CYP1A2, with lesser contributions from CYP2D6. Quetiapine and ziprasidone are metabolized by CYP3A4. In contrast to the 2 previously released second-generation antipsychotics, insufficient data are available to permit comment on the clinical safety of the 3 newest drugs in terms of metabolic drug–drug interactions.

Laboratory and in vivo metabolic studies of second-generation antipsychotics need to be expanded. In...
particular, both controlled studies and case reports are required to confirm the in vitro data and provide clinicians with indications and contraindications for concomitant therapy with these medications.

Acknowledgements: We are grateful to the Bebensee Foundation and the Canadian Institutes of Health Research (CIHR) for funding support. Dr. Prior is a CIHR Centennial Fellow.

Competing interests: None declared.

References


52. Seppälä NH, Leinonen EVJ, Lehtonen ML, Kivistö KT. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 1999;85:244-6.


Interactions between CYPs and second-generation antipsychotics


Currently there are several employment opportunities available for psychiatrists in St. John’s, Newfoundland. In-patient and out-patient positions are available for child, adolescent, adult and psycho-geriatric psychiatrists, as well as for development of subspecialty practice and remote services via telepsychiatry.

Remuneration may be arranged by fee-for-service, full or part-time salary and qualified candidates will be eligible for stipendiary academic appointment with the Discipline of Psychiatry at Memorial University of Newfoundland.

Successful candidates must obtain registration with the Newfoundland Medical Board and have FRCP certification in psychiatry or equivalent.

In accordance with immigration requirements, preference will be given to Canadian citizens and permanent residents of Canada.

For further information or to submit a letter of interest, please contact:

Dr. T. Cantwell
Clinical Chief
Mental Health Program
Health Care Corporation of St. John’s
St. John’s, Newfoundland A1E 4J8
Email cantwell@nf.sympatico.ca

Dr. T.S. Callanan
Chair, Discipline of Psychiatry
Faculty of Medicine
Health Sciences Centre
Memorial University of Newfoundland
St. John’s, Newfoundland A1B 3V6
Email ts.callanan@mun.ca

PSYCHIATRISTS

Memorial University of Newfoundland
HealthCare
Corporation of St. John’s
St. John’s, Newfoundland A1E 4J8

JPN-15

Rev Psychiatr Neurosci 2003;28(2)